Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.32 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.32 |
| ▸ | MAPK6 | Q16659 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19104288 | 0.86 | MAP2K4 (0.35) | MAPK1MAP2K4MAPKAPK2MAPK6 | |
| SCHEMBL17833922 | 0.80 | MAPK1 (0.35) | MAPK1MAP2K4MAPKAPK2MAPK6 | |
| SCHEMBL25667804 | 0.80 | MAPK1 (0.32) | MAPK1MAP2K4MAPKAPK2MAPK6 | |
| SCHEMBL22349084 | 0.77 | MAPK1 (0.35) | MAPK1 | |
| SCHEMBL19104285 | 0.77 | PDPK1 (0.42) | KDM4E | |
| SCHEMBL22328050 | 0.77 | MAPK1 (0.33) | MAPK1MAP2K4MAPKAPK2MAPK6 | |
| SCHEMBL19104228 | 0.77 | MAPK1 (0.33) | MAPK1MAP2K4MAPKAPK2MAPK6 | |
| SCHEMBL19786433 | 0.77 | MAPK1 (0.40) | MAPK1MAP2K4MAPKAPK2MAPK6 | |
| SCHEMBL17030758 | 0.77 | MAPK1 (0.33) | MAPK1MAP2K4MAPKAPK2MAPK6 | |
| SCHEMBL27051467 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11639346-B2 | Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS | ARAXES PHARMA LLC (US) | 2023-05-02 | — | — | US | disclosed |
| US-10745385-B2 | Covalent inhibitors of KRAS | ARAXES PHARMA LLC (US) | 2020-08-18 | — | — | US | disclosed |
| US-20170197945-A1 | 2-SUBSTITUTED QUINAZOLINE COMPOUNDS COMPRISING A SUBSTITUTED HETEROCYCLIC GROUP AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2017-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10745385-B2 | Covalent inhibitors of KRAS | KRAS, NRAS, HRAS | MAPK1 146/4885MAP2K4 340/4885MAPKAPK2 1080/4885 |
| US-11639346-B2 | Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS | KRAS, NRAS, HRAS | MAPK1 84/4885MAP2K4 165/4885MAPKAPK2 302/4885 |
| US-20170197945-A1 | 2-SUBSTITUTED QUINAZOLINE COMPOUNDS COMPRISING A SUBSTITUTED HETEROCYCLIC GROUP AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | MAPK1 197/4885MAP2K4 327/4885MAPKAPK2 794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.